NCT07180355View on ClinicalTrials.gov

A Study of SGT-212 Gene Therapy in Friedreich's Ataxia

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 22, 2025

Primary Completion Date

March 21, 2028

Study Completion Date

February 29, 2032

Conditions
Friedreich's Ataxia (FA)
Interventions
DRUG

SGT-212

Adeno-associated virus serotype AAVhu68 containing a codon-optimized complementary DNA (cDNA)

Trial Locations (2)

19104

The Children's Hospital of Philadelphia (CHOP), Philadelphia

43210

The Ohio State University, Columbus

All Listed Sponsors
lead

Solid Biosciences Inc.

INDUSTRY